Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
Date:5/17/2009

PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its two most advanced pipeline products NXL104 and NXL103 are the subject of four posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The ECCMID conference is taking place in Helsinki between 16th and 19th May 2009.

NXL104, Novexel's broad spectrum class A and C beta-lactamase inhibitor, is the subject of one poster. Novexel is currently conducting two Phase II clinical trials in patients with complicated urinary tract infections and complicated intra-abdominal infections with NXL104 in combination with ceftazidime. The poster provides in vitro data showing that a ceftazidime/NXL104 combination is rapidly bactericidal against a range of beta-lactamase-producing strains of Enterobacteriaceae, including E. coli, and Klebsiella. Data presented also showed that one of the most important factors affecting the pharmacodynamics of the combination is maintaining a critical concentration of the inhibitor (NXL104) to suppress beta-lactamase activity. (Poster P 1463).

NXL103, a novel oral streptogramin antibiotic, is the subject of three posters at the ECCMID conference. Novexel has recently completed a successful Phase II study with NXL103 in patients with community acquired pneumonia. The first of the three posters provides in vitro data showing that NXL103 was active against methicillin resistant Staphylococcus aureus (MRSA) and organisms responsible for lower respiratory tract infections, including Streptococcus pneumoniae and Haemophilus influenzae , (Poster P 1393). The second poster contains in vivo data demonstrating that, following oral administration, NXL103 was able to kill intracellular drug-resistant and non-drug-resistant strains o
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 Semler Scientific, Inc. (Nasdaq: ... that develops, manufactures and markets products that assist healthcare ... reported financial results for the first quarter ended March ... of 2015, Semler reported continued progress with year over ... revenue growth of 14%," said Doug Murphy-Chutorian , ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
(Date:4/30/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the fourth quarter and ... quarter and fiscal 2015 overview: , Revenues from ... up 33% over last year,s comparable quarter, and $202.6 ... Diluted EPS of $0.50 for the fourth quarter, up ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22
... Fla., Nov. 7 Results from the,latest ... were presented,today here at the American Heart ... relationship between decreased microvascular,function and cardiovascular risk., ... Itamar Medical,s ENDO-Pat device was the diagnostic ...
... on Aspirin Therapy Can Safely Take Aleve for ... Pain Without Compromising Cardiovascular Benefits, BOSTON, Nov. 7 ... of the American College of Rheumatology (ACR) showed that ... was,added to an aspirin therapy regimen, there was no ...
Cached Medicine Technology:New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease 2Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium 2Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium 3Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium 4
(Date:5/4/2015)... Today, Cireson reveals the following key announcements:, ... to strengthen core service & asset management solutions , ... Microsoft System Center and Cireson via Microsoft Azure in ... Company transitioning from a direct sales presence to 100% ... expanding new solutions for password reset management, gamification, self-service ...
(Date:5/3/2015)... Michigan (PRWEB) May 03, 2015 Barbara Crone has ... to enhance the well being of the men, women and families ... hospital, followed by providing care for families in the home. ... Adult Nurse Practitioner began wondering if I could complete their care ... my own children with my mentor Nurse Midwife, I knew it ...
(Date:5/3/2015)... San Francisco, CA (PRWEB) May 03, 2015 ... International (CFHI), announced it will be awarding the ... Scholars, Jennifer Knight and Selemawit Ghebrendrias, are the deserving ... and champion for global service, Harris Llewellyn Wofford. The ... global service and passion for global health. , ...
(Date:5/3/2015)... BolehVPN ” was featured on NewsWatch as part of its ... products available to consumers. Scott Steinberg, a technology expert and ... viewers how to protect their private information. , A lot ... even more so online. It helps everyone stay connected with ... In terms of work, the internet makes things more efficient. ...
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
Breaking Medicine News(10 mins):Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2
... LITTLE FALLS, N.J., Aug. 3 CANTEL MEDICAL CORP. ... has continued the expansion of its water purification and filtration segment ... LLC. G.E.M. designs, builds, installs and services high quality water ... business had pre-acquisition revenues of approximately $3.5 million. This cash ...
... the risk of trouble, expert says, , MONDAY, Aug. 3 ... physical education programs to battle the childhood obesity epidemic, the ... dramatically, Ohio State University researchers report. , In fact, ... to physical education (PE) increased 150 percent -- from 24,000 ...
... BERKELEY HEIGHTS, N.J., Aug. 3 Authentidate ... worldwide provider of secure Health Information Exchange and ... of America, Inc., a leading provider of home ... South Carolina, will implement Authentidate,s Inscrybe(TM) Healthcare web-based ...
... , Expert recommends parents and schools ... ANN ARBOR, Mich., Aug. 3 As a bright, young ... had everything going for her. , , But when ... on hand, Laura landed on her head fracturing her neck and damaging ...
... , ARDEE, Ireland, Aug. 3 Warner Chilcott Limited ... two Paragraph IV Certification Notices from Lupin Ltd. ("Lupin"). The ... Abbreviated New Drug Applications (ANDAs) by Lupin for generic versions of ... , , LOESTRIN 24 FE, which was launched ...
... , , LEAGUE CITY, Texas, Aug. ... been dedicated to the insurance needs of seniors, with an unyielding ... Agent. This has never been more evident than in the introduction ... 2009. , , With the advent of the ...
Cached Medicine News:Health News:Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment 2Health News:Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment 3Health News:Gym Class Injuries Up 150 Percent 2Health News:Gym Class Injuries Up 150 Percent 3Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 2Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 3Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 4Health News:Cheerleading is Leading Cause of Catastrophic Injury in Young Women 2Health News:Cheerleading is Leading Cause of Catastrophic Injury in Young Women 3Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 2Health News:Warner Chilcott Announces Receipt of Paragraph IV Certification Notices 3Health News:SLAICO Takes the Medicare Supplement Application Online - Eliminating All Paperwork Offline. 2